9 completed, 2 active not recruiting, 2 terminated, 1 no longer available. 14 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 7, Active not recruiting 2, Terminated 2, Suspended 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Not applicable | 1 | Recruiting 1 |
Follow PSA Progression: new trials by email Literature Review of PSA Progression trials Research Report on PSA Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRI-Assisted Guidance for Non-Essential Tissue Sampling Paired Prostate Biopsy Cohort (TB + SB) - PSA Progression, PSA | Not applicable | Recruiting | Shanghai East Hospital | 1235 | 2026-04-05 | 2026-06-24 |
| White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA Clinical Observation, Patient Observation, Questionnaire Administration - Prostate Adenocarcinoma, PSA Failure | Phase 2 | Suspended | City of Hope Medical Center | 133 | 2021-05-10 | 2026-11-04 |
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer Decitabine, Enzalutamide - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-04-15 | 2022-10-05 | |
| Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer Gallium Ga 68 DOTA-NeoBOMB1, Gallium Ga 68 PSMA-R2 - Prostate Adenocarcinoma, PSA Progression | Phase 2 | Completed | Andrei Iagaru | 27 | 2020-12-15 | 2024-01-30 |
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer Apalutamide, Stereotactic Body Radiation Therapy - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | University of California, San Francisco | 26 | 2019-12-17 | 2026-01-21 |
| sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Recombinant EphB4-HSA Fusion Protein - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Unknown | Northwestern University | 14 | 2019-09-20 | 2022-04-27 |
| Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer Enzalutamide, Venetoclax - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | Roswell Park Cancer Institute | 10 | 2019-08-02 | 2023-10-16 |
| Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery Antiandrogen Therapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy - PSA Level Greater Than 0.03, PSA Progression | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 92 | 2019-01-29 | 2025-11-06 |
| Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Carboplatin, Docetaxel, Laboratory Biomarker Analysis - ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Terminated | University of Washington | 18 | 2018-08-24 | 2026-08-26 |
| Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 15 | 2018-06-07 | 2023-05-03 |
| 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 937 | 2018-04-02 | 2021-09-30 |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer ESK981 - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 13 | 2018-03-08 | 2023-07-14 |
| Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Abiraterone Acetate, Apalutamide, Cabazitaxel - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 196 | 2016-05-18 | 2026-09-14 |
| Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway Carboplatin, Docetaxel, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | University of Washington | 14 | 2016-01-26 | 2022-11-17 |
| Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide Enzalutamide, Laboratory Biomarker Analysis, Pembrolizumab - Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer | Phase 2 | Completed | OHSU Knight Cancer Institute | 58 | 2014-11-18 | 2026-10-28 |
| Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer Selinexor - Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer | Phase 2 | Terminated | University of California, San Francisco | 14 | 2014-09-02 | 2018-06-26 |
| Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Completed | OHSU Knight Cancer Institute | 41 | 2013-03-12 | 2020-09-28 | |
| F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer Computed Tomography, Fluorine F 18 DCFPyL, Laboratory Biomarker Analysis - Prostate Adenocarcinoma, PSA Level Greater Than 0.2 | No longer available | Andrei Iagaru | 2022-01-21 |
Prostatic Neoplasms (12) · Disease Progression (1)
Genital Diseases (12) · Genital Diseases, Male (12) · Genital Neoplasms, Male (12) · Male Urogenital Diseases (12) · Neoplasms (12) · Neoplasms by Site (12) · Prostatic Diseases (12) · Urogenital Diseases (12) · Urogenital Neoplasms (12) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
enzalutamide (4) · Carboplatin (3) · Docetaxel (2) · Magnetic Resonance Spectroscopy (2) · Radiosurgery (2) · apalutamide (2) · pembrolizumab (2) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · 68Ga-DKFZ-PSMA-11 (1) · Abiraterone Acetate (1) · Androgen Antagonists (1) · CTLA-4 Antigen (1) · Decitabine (1) · Injections (1) · Ipilimumab (1)
Andrei Iagaru (2) · Barbara Ann Karmanos Cancer Institute (2) · Jonsson Comprehensive Cancer Center (2) · OHSU Knight Cancer Institute (2) · Roswell Park Cancer Institute (2) · University of California, San Francisco (2) · University of Washington (2) · City of Hope Medical Center (1) · M.D. Anderson Cancer Center (1) · Northwestern University (1) · Shanghai East Hospital (1)
United States (17) · China (1)
Andrei Iagaru (2) · Gurkamal Chatta (2) · Heather H. Cheng (2) · Abhinav Deol, M.D. (1) · Amar Kishan, MD (1) · Ana Aparicio (1) · Charles Ryan, MD (1) · Clayton S Lau (1) · Elisabeth I. Heath (1) · Jeremie Calais (1) · Joshi Alumkal (1) · Julie Graff, M.D. (1) · Maha H Hussain, M.D. (1) · Rahul Aggarwal, MD (1)
PMID 29487219, PMID 32616555, PMID 33602654, PMID 33674398, PMID 35405009, PMID 36210299, PMID 36934894, PMID 37981040, PMID 38664016, PMID 39227508, PMID 39390760, PMID 40372727, PMID 41315064, PMID 41698328
P30CA022453 (2), P30CA015704 (1), P30CA033572 (1), P30CA060553 (1), P50CA097186 (1)